E115: Benralizumab for EGPA - the MANDARA Study

Quick rundown of an important rheumatology RCT this week, discussing the IL-5 inhibitor benralizumab for the treatment of relapsing/refractory EGPA. 

 

MANDARA Study: https://www.nejm.org/doi/full/10.1056/NEJMoa2311155